US Patent

US7795243 — Penem prodrugs

Method of Use · Assigned to Pfizer Inc · Expires 2029-06-03 · 3y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects orally bioavailable prodrugs of sulopenem, such as Col-Probenecid, and their preparation, formulation, and use to treat and prevent infections in mammals.

USPTO Abstract

Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.

Drugs covered by this patent

Col-Probenecid (probenecid) · Pfizer Inc.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4026`	—	Col-Probenecid

Patent Metadata

Patent number: US7795243
Jurisdiction: US
Classification: Method of Use
Expires: 2029-06-03
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.